Experimental sickle cell disease drug gets PRIME status

29th June 2017 Uncategorised 0

Global Blood Therapeutics’ GBT440 has become the first potential treatment for sickle cell disease to be accepted onto the European Medicines Agency’s regulatory support programme PRIME.

More: Experimental sickle cell disease drug gets PRIME status
Source: News